

August 14, 2018

Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
21st Floor, Fort
Mumbai – 400 023

Dear Sirs,

Sub: Un-Audited Financial Results for the Quarter ended 30th June 2018 – Reg
Ref: 1) Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations 2015 – Reg
2) Our letter dated 03.08.2018
3) Ref Scrip Code 526783

We request your kind attention to the above subject and references. We wish to inform you that at the Board Meeting held today, the Board of Directors of the Company have taken on record and approved the Un-Audited Financial Results for the Quarter ended 30th June 2018. We, enclose herewith the Un-Audited Financial Results and the Auditors' Limited Review Report.

As per the Listing Regulations, the Company has also made arrangement for release of the Un-Audited Financial Results in the News Papers and upload the same on our website at www.dragarwal.com.

Kindly take the above information on record.

Thanking you,

Yours truly,



DR. AMAR AGARWAL
CHAIRMAN CUM MANAGING DIRECTOR
DR. AGARWAL'S EYE HOSPITAL LIMITED

Encl.: As above

Registered Office

3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai - 600 006.
Tel: 91-44-3991 6600 Fax: 91-44-3991 6645
Corporate ID Number: L85110TN1994PLC027366 GST No. 33AAACD2373G1Z2
Email: dragarwal@vsnl.com | Website: www.dragarwal.com



Dr. Agarwal's Eye Hospital Limited

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-39916669, Website : www.dragarwal.com, E-mail : investor@dragarwal.com, CIN : L85110TN1994PLC027366
Statement of Unaudited Financial Results for the Quarter Ended 30 June 2018

Amount in Rs. Lakhs

S.No.	Particulars	Quarter Ended			Year ended
		30-Jun-18	31-Mar-18	30-Jun-17	31 March 2018
		Unaudited	(Refer Note 4)	Unaudited	Audited
1	Income				
	(a) Revenue from Operations	4,439.10	3,757.96	4,183.32	15,332.13
	(b) Other Income	43.46	66.45	20.86	230.00
	Total Income	4,482.56	3,824.41	4,204.18	15,562.13
2	Expenses				
	(a) Purchase of Stock-in-Trade	517.10	523.43	706.67	1,896.47
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(123.53)	(19.84)	(254.53)	(81.82)
	(c) Consumables	521.53	397.84	422.01	1,541.74
	(d) Consultancy Charges	580.68	512.13	496.64	2,002.75
	(e) Employee Benefit Expenses	852.35	741.26	762.36	3,198.03
	(f) Finance Costs	47.37	95.50	53.25	259.04
	(g) Depreciation and Amortisation Expense	229.27	239.23	214.00	978.18
	(h) Rent	421.79	443.03	423.12	1,717.98
	(i) Other Expenses	696.73	718.26	640.75	2,713.67
	Total Expenses	3,743.29	3,650.84	3,464.27	14,226.04
3	Profit before Exceptional Items and Tax (1-2)	739.27	173.57	739.91	1,336.09
4	Exceptional Items	-	-	-	-
5	Profit before Tax (3-4)	739.27	173.57	739.91	1,336.09
6	Tax Expense				
	- Current Tax (including prior years)	235.80	146.55	295.30	644.35
	- Deferred Tax	(19.53)	110.41	(39.11)	14.22
7	Net Profit / (Loss) after tax for the period (5-6)	523.00	(83.39)	483.72	677.52
8	Other Comprehensive Income				
	(a) Items that will not be reclassified to the Statement of Profit and Loss				
	- Actuarial loss on defined benefit obligation	(9.55)	(13.32)	(8.35)	(38.19)
	- Tax on Items that will not be reclassified to the Statement of Profit and Loss	2.78	2.51	2.89	11.12
	(b) Items that will be reclassified to the Statement of Profit and Loss	-	-	-	-
	Total Other Comprehensive Loss (net of tax)	(6.77)	(10.81)	(5.46)	(27.07)
9	Total Comprehensive Income / (Loss) (7+8)	516.23	(94.20)	478.26	650.45
10	Paid-up equity share capital (Face value Rs.10/- each)	470.00	470.00	470.00	470.00
11	Reserves (Other Equity)				3,035.91
12	Earnings Per Equity Share (EPS) (of Rs. 10/- each)				
	(a) Basic	11.13	(1.77)	10.29	14.42
	(b) Diluted	11.13	(1.77)	10.29	14.42
		(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

- The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their Meeting held on 14 August 2018. The above results for the quarter ended 30 June 2018 has also been subject to limited review by the Statutory Auditors of the Company.
- Effective 1 April 2018, the Company has adopted Ind AS 115 'Revenue from Contracts with Customers'. The application of Ind AS 115 did not have any material impact on the financial results of the Company.
- The Company operates in a single segment i.e. "Eye Care related Sales and Services" and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- The figures for the quarter ended 31 March 2018 are the balancing figures between the audited figures for the year ended 31 March 2018 and the unaudited year to date figures for the nine months ended 31 December 2017, which were subject to limited review by the Statutory Auditors.

By order of the Board

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684

Place : Chennai
Date : 14 August 2018



INDEPENDENT AUDITOR'S REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter ended 30 June 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been in accordance with the aforesaid Indian Accounting Standard 34 and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Jaideep S. Trasi
Partner
(Membership No. 211095)

CHENNAI, 14 August 2018
JT/RB/2018/60

